PD 115934

Drug Profile

PD 115934

Alternative Names: NSC 366140; Pyrazoloacridine; PZA

Latest Information Update: 25 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer National Institutes of Health (USA); Pfizer
  • Class Acridines; Pyrazoles; Small molecules
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 25 Sep 2006 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 25 Sep 2006 Discontinued - Phase-II for Colorectal cancer in USA (IV-infusion)
  • 25 Sep 2006 Discontinued - Phase-II for Endometrial cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top